Categories
Category: Gilead
Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain
Visiongain Reports Ltd Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS…
Translational Regenerative Medicine market is estimated to
Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading…
Ten NK cell therapy companies to look out for this year
Natural killer (NK) cells are white blood cells that are a part of the body’s defense mechanism. These cells are on the lookout for any kind of disruption in the immune system, and can kill diseased cells like tumor cells. NK cells are being used in clinical applications to treat…
The best countries for biotech according to the OECD
The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech companies (2,840) and an R&D intensity added value of 17%, the U.S. remains a strong leader in the industry. But…
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open
Key Points Question What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings In this cohort study of 184 patients enrolled in the phase 3 trial…
Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone —…
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
Drug the undrugable, treat the untreatable, the revolution in drug development is happening all around us The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval,…
Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL
T-cell engaging therapeutic approaches have significantly changed the treatment paradigm for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in recent years. “They are, by a wide margin, the most impactful new therapies for all B-cell lymphomas, but especially DLBCL, in the last 40 years, if not ever,” said Joshua…
Complete Interim Response, SCT Beats CAR T
Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…
Five Dubai Biopharma Companies To Know About
The Middle East’s industry is rapidly growing, with several key players emerging in the region. Notably, Qatar, Saudi Arabia, and the United Arab Emirates (UAE) are at the forefront of this expansion. Our focus today zeros in on the UAE, particularly Dubai and its biopharma companies, renowned for being one…
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…
Red Biotechnology Market Size, Share, Growth Report and Forecast 2024-2032
PRESS RELEASE Published December 11, 2023 According to the report by Expert Market Research (EMR), the global red biotechnology market is projected to grow at a CAGR of 6.20% between 2024 and 2032. Aided by the escalating demand for therapeutic solutions, innovative drugs, and genetic engineering, the market is expected to…
Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS
“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…
Principal Scientist – Bioinformatics (Clinical Development) job with Gilead Sciences, Inc.
Principal Scientist – Bioinformatics (Clinical Development)United States – California – Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living…
Gene Therapy Market estimated to grow according to forecasts
Allied Market Research has published a study report Gene Therapy Market Size is Anticipated to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% Allied Market Research published a report, titled, “Gene Therapy Marketby Vector Type (Viral Vector, Non-Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by…
Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups
Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…
Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023
PRESS RELEASE Published December 6, 2023 DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by…
Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.
DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. {Delhi, India} To strategically…
What does it mean for oncology and beyond?
Chimeric antigen receptor (CAR) T-cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR T-cell…
DNA Sequence in Pfizer COVID-19 Vaccine Could Spur New Lawsuits: Lawyers
A woman walks by Pfizer’s headquarters in New York City in a file image. (Kena Betancur/AFP via Getty Images) Pfizer and its partner BioNTech could be open to lawsuits for including a DNA sequence in their COVID-19 vaccine. The Public Readiness and Emergency Preparedness Act, known as the PREP Act,…
Car T Cell Therapy Market will generate new growth opportunities 2023-2030
PRESS RELEASE Published November 29, 2023 The research study conducted by Coherent Market Insights on the “Car T Cell Therapy Market” spans over 100 pages and delves into various facets of this market. It analyzes the business strategies adopted by emerging industry players, examines the geographical scope, dissects market segments,…
3 Biotech Stocks That Could Be Multibaggers in the Making
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization. However, the path to revolutionizing healthcare is not without its challenges. Many of the top…
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
For Immediate Release Chicago, IL – November 24, 2023 – Today, Zacks Equity Research discusses Gilead Sciences, Inc. GILD, CRISPR Therapeutics AG CRSP, ACADIA Pharmaceuticals Inc. ACAD, Dynavax DVAX and Ligand Pharmaceuticals Inc. LGND. Industry: Biotech Link: www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright It has been a choppy ride for the biotech industry in 2023…
A Deep Dive into Trends, Players, and Growth
The gene therapy market has evolved into a juggernaut in the healthcare sector, displaying an extraordinary trajectory of growth. As of 2023, the gene therapy market has surged to a remarkable value of USD 6.36 billion, and the projection for the forthcoming years is nothing short of astonishing. Forecasts indicate…
The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma
B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
Review doi: 10.1016/j.blre.2023.101140. Online ahead of print. Affiliations Expand Affiliations 1 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America. 2 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America; Case Comprehensive Cancer Center, Cleveland, OH,…
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…
CAR T Cell Therapy Market Demands, Industry Analysis and Forecast 2032 | Taiwan News
Report Ocean has recently published a revised figures report on the worldwide CAR T Cell Therapy market. Growth prospects and difficulties are noted in the paper. A tool for evaluating the potential for new goods and services is the constraints and opportunity analysis. This aids businesses in locating and forecasting…
Who are the leading innovators in rDNA expression systems for the pharmaceutical industry?
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity. Identifying where a particular innovation is on this…
Eight biotech companies tackling infectious diseases head-on
Infectious diseases are diseases that are caused by pathogens that enter the body, hijack the body’s immune system and multiply, causing an infection. Five of the deadliest infectious diseases are measles, tuberculosis, malaria, diarrhoeal disease and influenza, according to the World Economic Forum. While Our World in Data statistics suggest…
Biotechnology Poised For Disruptive And Explosive Growth|Gilead Sciences Inc., Regeneron Pharmaceuticals Inc.
HTF Market Intelligence published a new research document of 150+pages on “Biotechnology Market Insights, to 2028″ with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Biotechnology market was mainly…
major antitrust cases in recent years
Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby…
Exploring Opportunities in the Bioinformatics
“Bioinformatics and Computational Biology Market “Worldwide Market Reports offers a UP-TO 70% discount on Bioinformatics and Computational Biology Market Reports on Single User Access and Unlimited User Access” The latest research study released by Worldwide Market Reports on “Bioinformatics and Computational Biology Market 2023 Forecast to 2030″ research provides accurate…
Axicabtagene Ciloleucel Works in Refractory DLBCL
Axicabtagene Ciloleucel (Yescarta®), developed by Kite, appears to outperform the effectiveness of epcoritamab and gllofitamab in the treatment of refractory diffuse large B-cell lymphoma (DLCBL), according to a recently published press release. Approximately 40% of patients with DLBCL are refractory or experience relapse after receiving treatment with standard-of-care chemotherapy with…
SAP Financial Results Q3 2023
SAP Financial Results Q3 2023 SAP financial results for Q3 2023 have been announced, showing a strong performance for the quarter and bright prospects for the future, so this week IgniteSAP will provide a summary of the report and discuss what these numbers mean for SAP and the wider ecosystem…
Biotech’s fight for liver health
NASH is one of the most common reasons for a patients receiving a liver transplant. The condition is a severe form of non-alcoholic fatty liver disease (NAFLD), whereby fat builds up on the liver, potentially leading to liver damage or cirrhosis. And, yet, despite the severity of the disease, there…
Gene Therapy Market To Soar At 18.5% CAGR, Reaching $10.1 Billion By 2032 Themarketpublicist
(MENAFN– Ameliorate Digital Consultancy) As of 2021, the global gene therapy market was valued at an estimated $1.55 billion USD. This market is poised for significant expansion, with a projected increase from $1.85 billion in 2022 to a remarkable $10.1 billion by 2032, reflecting a robust compound annual growth rate…
BioSpace hiring Graduate Intern – Bioinformatics in Foster City, California, United States
United States – California – Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the…
ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease
A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market 2023 : Research Key Players, Industry Overview, Cost Structure Analysis, Supply Chain and forecast to 2030
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Size Projections : The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period (2023-2030). A complete study of the global Relapsed or Refractory Diffuse Large B-cell Lymphoma…
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology
Key Points Question How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…
Cell And Gene Therapy Market Outlook and Opportunities in Grooming Regions 2030
Cell And Gene Therapy Market Size Projections : The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030). Global Cell And Gene Therapy Market 2023 research report represents a detailed overview of the current market situation and…
Cytokine Release Syndrome Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market
PRESS RELEASE Published October 4, 2023 “Cytokine Release Syndrome Market” DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain,…
FDA starts swift review of Regeneron’s CD20 bispecific
The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class. The US regulator is reviewing odronextamab for two forms of B-cell non-Hodgkin lymphoma (NHL) – follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) – in patients…
Gilead Sciences Statement on Phase 3 Obeldesivir Clinical Trials in COVID-19: BIRCH Study to Stop Enrollment While OAKTREE Study Nears Full Enrollment -September 28, 2023 at 08:40 am EDT
Foster City, Calif.,September 28, 2023 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has stopped patient enrollment in BIRCH (Study GS-US-611-6273), a Phase 3 study evaluating the efficacy and safety of obeldesivir compared with placebo in non-hospitalized participants who are at high risk for developing severe COVID-19. This…
Novel Sequencing Strategies May Expand Localized and Metastatic Breast Cancer Treatment Landscapes
Jairam Krishnamurthy, MD, FACP An influx of research on the horizon may contribute to improved treatment outcomes for patients with early-stage and metastatic HER2-positive breast cancer, according to Jairam Krishnamurthy, MD, FACP. He added that additional data, such as long-term follow-up data from the phase 3 NATALEE trial (NCT03701334) are…
Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML
Gilead Discontinues Phase 3 ENHANCE-2 Trial | Image Credit: ©freshidea – stock.adobe.com The phase 3 ENHANCE-2 trial (NCT04778397) examining the frontline combination of magrolimab and azacitidine (Vidaza) vs physician’s choice of venetoclax (Venclexta) with azacitidine or intensive chemotherapy in patients with acute myeloid leukemia and TP53 mutations has been discontinued,…
Pegozafermin improves fibrosis in patients with NASH, could advance to phase 3 development
September 22, 2023 2 min read Source/Disclosures Published by: Disclosures: Loomba reports financial relationships with 89bio, Aardvark Therapeutics, Allergan, Altimmune, Amgen Inc., Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CohBar, Eli Lilly, Galectin, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Glympse bio, Hanmi Pharmaceutical, Hightide, Inipharm, Intercept Pharmaceuticals, Inventica, Ionis Pharmaceuticals, Janssen…
Diffuse Large B-cell Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
PRESS RELEASE Published September 21, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes…
Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) versus irbesartan. FILSPARI demonstrated long-term kidney function preservation and achieved a clinically…
Diffuse Large B-cell Lymphoma Market to Show Immense Growth
New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) — Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda The DLBCL market has a diverse pipeline, with the emergence of…
Five biotech companies taking Los Angeles by storm
Known throughout history for being home to the iconic scene of Hollywood, in recent years Los Angeles has also become a thriving biotech hub, after years of playing second fiddle in the U.S. to the likes of South San Francisco and Boston. In this article, we take a look at…
Cirrhosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)
PRESS RELEASE Published September 18, 2023 DelveInsight’s, “Cirrhosis Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Cirrhosis pipeline landscape. It covers the Cirrhosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage,…
Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma
“ALYCANTE is the first study to assess [axi-cel] as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population,” according to Roch Houot, professor and head of the Haematology Department at University Hospital of Rennes, France. Treatment with axicabtagene…
Shoreline Smashes Fate Thx and Whitehead in Legal Battle Over iPSCs
Shoreline Biosciences Wins a Comprehensive Summary Judgment Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use September 7, 2023, SAN DIEGO – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural…
Remdesivir increases mtDNA copy number causing mild alterations to oxidative phosphorylation
Coronavirus disease (COVID-19) – World Health Organization. www.who.int/emergencies/diseases/novel-coronavirus-2019. Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021). Article CAS PubMed PubMed Central Google Scholar Kang, L. et al. A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation. Cell…
Gene Expression Market Poised for 8% CAGR Growth During Forecast Period 2022 to 2029
PRESS RELEASE Published September 13, 2023 In a recently released analysis titled “Gene Expression Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2029,” Exactitude Consultancy, a reputable market research firm, provided data. The report offers a thorough overview of the market, including data on market size, trends, and…
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Growth in Future Scope 2023-2030
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Size Projections : The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period (2023-2030). Relapsed or Refractory Diffuse Large B-cell Lymphoma Market report provides an in-depth analysis…
Cell And Gene Therapy Market Highlighting Regional Revenue Share Dominance during 2023-2030
Cell And Gene Therapy Market Size Projections : The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030). Cell And Gene Therapy Market report provides an in-depth analysis of the current market landscape. It covers market size,…
Biotechnology Market is Expanding USD 3,995.22 Billion By 2032
According to Precedence Research, the global biotechnology market was valued at USD 1,224.31 billion in 2022 and is estimated to be worth around USD 3,995.22 billion by 2032, expanding at a healthy CAGR of 12.5% from 2023 to 2032. The global biotechnology market stands at the forefront of scientific innovation,…
Gene Therapy Market 2023 | Worldwide Industry Gross Margin, Future Demand, Leading Player, Progression Status and Forecast till 2029 by Key Players
PRESS RELEASE Published August 30, 2023 Gene Therapy ****Everything You Need to Know About Gene Therapy everything is Here….! The Comprehensive study on Gene Therapy Market includes historical data as well as share, size, and projection information for the major players, geographies, applications, and product categories for the years 2023 to…
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
Roche’s inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients. The data was posted on the company’s website Tuesday and discovered by Wall Street analysts. The trial, SKYSCRAPER-01, is assessing the effect…
Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Analysis
Las Vega (Nevada), United States //- As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Diffuse Large B-cell Lymphoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies…
US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment
The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes Representational image Gilead Sciences announced that the US Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab…
Top 3 Tech Stocks in the A-Rated Industry on Wall Street
The U.S. tech industry is one of the most dynamic and innovative in the world. Companies in this space constantly develop new products and services and disrupt traditional industries. Despite facing multiple macroeconomic headwinds over the past two years, the sector is poised to rake in significant profits in the…
Diffuse Large B-cell Lymphoma Therapeutics Market 2023-2032:
Diffuse Large B-cell Lymphoma Therapeutics Market The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies increasing incidence of diffuse large B-cell…
Biotechnology Market to Worth Around USD 3,995.22 Billion by 2032
Ottawa, Aug. 14, 2023 (GLOBE NEWSWIRE) — The global biotechnology market size accounted for USD 1,224.31 billion in 2022, a study published by Towards Healthcare a sister firm of Precedence Research. According to Steve Jobs, the most significant advancements of the 21st century would arise from the convergence of biology…
Gene Therapy Market to hit USD 44.5 billion by 2032, says
Selbyville, Delaware, Aug. 07, 2023 (GLOBE NEWSWIRE) — Gene Therapy Market size is expected to be worth USD 44.5 billion by 2032. The growing adoption of personalized medicine is generating lucrative opportunities for market growth. Precision medicine emphasizes the identification of genetic factors underlying diseases and the development of targeted therapies. Gene…
SHORELINE BIOSCIENCES TO PARTICIPATE AT THE 2023 WEDBUSH PACGROW HEALTHCARE CONFERENCE
SAN DIEGO, Aug. 3, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNK) and macrophages (iMACs), today announced that it will participate in the 2023 Wedbush Pacgrow Healthcare Conference taking place August 8-9,…
Trial Evaluating Magrolimab Plus Azacitidine in Higher-Risk MDS Discontinued
Gilead has decided to discontinue the phase 3 ENHANCE study evaluating magrolimab plus azacitidine for the first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS). Magrolimab is an investigational monoclonal antibody that binds to CD47 and blocks the inhibitory CD47-signal regulatory protein (SIRPα) interaction. This enhances the ability of macrophages…
Gilead Discontinues Phase 3 ENHANCE Trial in Higher-Risk MDS
Gilead Discontinues Phase 3 ENHANCE Trial in Higher-Risk MDS Gilead has announced that the phase 3 ENHANCE trial (NCT04313881), which was investigating frontline magrolimab and azacitidine (Vidaza) vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome (MDS), will no longer be continuing. The company cited futility as the reason…
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials | News
SAN DIEGO–(BUSINESS WIRE)–Jul 27, 2023– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, an investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals. If…
Medicxi announces $400M fund for life science companies
Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients. Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson),…
AbbVie’s Epcoritamab Gets CHMP Nod for DLBCL
Source – AbbVieAbbVie and Genmab’s potential blockbuster drug epcoritamab has received a favorable recommendation for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of non-Hodgkin’s lymphoma. The European Medicines Agency’s human medicines committee (CHMP) has issued a positive opinion on…
Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS
The phase 3 ENHANCE trial (NCT04313881) evaluating the first-line combination of magrolimab and azacitidine (Vidaza) vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome (MDS) has been discontinued due to futility at a planned analysis, according to an announcement from Gilead Sciences.1 Trial investigators and the company are evaluating…
A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development
A-Alpha Bio Their platforms have already shown a great deal of promise through their internal pipeline and partnerships, and we believe they have the potential to redefine our understanding of protein-protein interactions and accelerate the development of innovative and high-impact therapeutics. SEATTLE (PRWEB) July 25, 2023 A-Alpha Bio, a…
CAR T Cell Therapy Market Research Report 2023 Size, Share, Business Strategies Growth Forecast and Industry Statistics Until 2031
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen…
Gilead Sciences (GILD) To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in…
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later….
Vascular level inflammatory response induced by COVID-19
Runlong Lin,1,2 Jing Yu,2 Aijuan Tian,2 Xiaomei Wang,2 Xin Yuan,2 Wengui Xu,1 Wenli Xie3 1Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s…
Diffuse Large B-cell Lymphoma (DLBCL) Market Report 2032:
Diffuse Large B-cell Lymphoma (DLBCL) Market (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…
Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Gilead Sciences, Inc. announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population….
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in…
ctDNA negative status contributes to positive outcomes for DLBCL
Source/Disclosures Published by: Source: Herrera, A, et al. Abstract 7523. Presented at: American Society of Clinical Oncology Meeting; June 2-6, 2023; Chicago. Disclosures: Herrera reports consulting and funding from Abbvie, ADC Therapeutics, Adicet Bio, AstraZeneca/MedImmune, Bristol-Myers Squibb, Caribou Biosciences, Genentech/Roche, Genmab, Gilead Sciences, Karyopharm Therapeutics, Kite, a…
Seven pharma companies form alliance to prepare for pandemics
Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The alliance creation is in support of the 100 Days Mission,…
Recent Developments and Advancements in Genetic Medicine
PRESS RELEASE Published July 17, 2023 The global Gene Therapy Market is expected to be valued $7.3 billion in 2023 and $17.2 billion by 2030, increasing at a CAGR of 18.6% between 2023 and 2030. The new research report consists of a market industry trend analysis. The new research study…
is a bioinformatics certificate worth it
Application criteria may vary depending on the program you wish to be admitted to. Microbiology Course. Hello all, I have a BS in molecular biology, and after working for a bit and dipping my feet in the wet lab, I realize it is not the place I want to be….
Nurix Therapeutics Reports Second Quarter Fiscal 2023
Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Received $20 million licensing payment from Gilead for NX-0479, an oral IRAK4 degrader for the treatment of rheumatoid arthritis and inflammatory diseases Maintained strong…
3 Biotech Stocks to Buy for Long-Term Gains
Biotech stocks may be one of the big winners if the Federal Reserve is almost finished raising interest rates. CRISPR Therapeutics is at the forefront of gene editing, which may be a generational opportunity for investors. Vertex Pharmaceuticals has a partnership with CRISPR Therapeutics. With over 61 candidates in its…
How to accelerate the generation of single-cell clones
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), genome engineering of cell lines, facilitate target discovery. It provides an excellent disease model for preclinical research, particularly in chimeric antigen receptor T-cell therapy. The primary challenge in cell engineering remains the generation of single-cell clones. Current approaches range from manual limiting dilution…
LeadStack Inc. hiring Research Scientist – Bioinformatics II in Foster City, California, United States
LeadStack Inc. is an award-winning, one of the nation’s fastest-growing, certified minority-owned (MBE) staffing services provider of contingent workforce. As a recognized industry leader in contingent workforce solutions and Certified as a Great Place to Work, we’re proud to partner with some of the most admired Fortune 500 brands in…
The Report provides complete market analysis of Biotechnology market and reports related to this market, forecasted for period from 2023
PRESS RELEASE Published July 10, 2023 Biotechnology Market The Biotechnology market was valued at 528940 million in 2023 and is projected to reach US$ 856060 million by 2030, at a CAGR of 7.1% during the forecast for period from 2023 – 2030. The biotechnology market research report provides insights into…
Phase 3 Data Now Published in NEJM
TOPLINE: Nearly half of patients with chronic hepatitis D virus (HDV) infection treated with bulevirtide achieved the combined primary endpoint of reduced or undetectable HDV RNA levels and normalized alanine aminotransferase (ALT) levels after 48 weeks in the phase 3 trial. METHODOLOGY: A total of 150 patients with chronic HDV…
The Oncology Precision Medicine market insights include historical trends and future projections, and market size with a growth rate of 13.6% from 2023 to 2030.
PRESS RELEASE Published July 3, 2023 Executive Summary The global Oncology Precision Medicine market is expected to grow at a CAGR of 13.6% over the forecast period of 2023-2030. The growth can be attributed to the increasing incidence of cancer cases, the advent of new technologies, and the rising demand…
AstraZeneca, Daiichi Cancer Drug’s Phase 3 Results Clouded by Toxicity Concerns
A targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo met a key goal in a pivotal lung cancer study, but the companies also revealed an unspecified number of patient deaths, clouding the preliminary results reported on Monday. The drug, datopotamab deruxtecan, is part of a multi-billion dollar partnership between…
ASCO Reading Room | Loretta Nastoupil, MD, on the Rapidly Evolving Treatment Landscape for DLBCL
Several promising therapies for newly diagnosed and relapsed diffuse large B-cell lymphoma (DLBCL) patients have been recently approved or are in the final stages of development, including enhanced monoclonal antibodies, antibody-drug conjugates, and T-cell–engaging therapies. Over the last few years, the bottom-line approach to DLBCL, the most common B-cell lymphoma,…
CAR-T Cell Therapy Market Production & Demand by 2031
PRESS RELEASE Published June 27, 2023 The global CAR-T Cell Therapy Market Report 2022 covers all the comprehensive industry factors that are closely affecting the growth of the CAR-T Cell Therapy market alongside the investigation of the latest industry trends as well as new developments in the industry across the…
Industrial-Scale Stem Cells Are Here
The hopes and dreams of regenerative medicine and the use of stem cells to treat or cure diseases have been a beacon of promise for 25 years. But after a roller coaster ride of scientific breakthroughs, clinical setbacks, policy wrangles, and an explosion of suspiciously charlatan clinics pushing unproven treatments,…
Bulevirtide Shows Promise in Treating Chronic Hepatitis Delta Infection Week 96 Results from MYR301 Phase 3 Clinical Trial
On June 23, 2023, Gilead Sciences Inc released the Week 96 results from the MYR301 Phase 3 clinical trial, which evaluated the use of bulevirtide for chronic hepatitis delta (HDV) infection. Bulevirtide is currently the only approved treatment for HDV in Europe, but it has not yet been approved in…